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Background: Cough is an extremely common problem in pediatrics, mostly triggered and perpetuated by
inflammatory processes or mechanical irritation leading to viscous mucous production and increased sensitivity of
the cough receptors. Protecting the mucosa might be very useful in limiting the contact with micro-organisms
and irritants thus decreasing the inflammation and mucus production. Natural molecular complexes can act as a
mechanical barrier limiting cough stimuli with a non pharmacological approach but with an indirect anti-inflammatory
action.
Objective: Aim of the study was to assess the efficacy of a medical device containing natural functional components
in the treatment of cough persisting more than 7 days.
Methods: In this randomized, parallel groups, double-blind vs. placebo study, children with cough persisting more than
7 days were enrolled. The clinical efficacy of the study product was assessed evaluating changes in day- and night-time
cough scores after 4 and 8 days (t4 and t8) of product administration.
Results: In the inter-group analysis, in the study product group compared with the placebo group, a significant
difference (t4 study treatment vs. t4 placebo, p = 0.03) was observed at t4 in night-time cough score.
Considering the intra-group analysis, only the study product group registered a significant improvement from t0 to t4
in both day-time (t0 vs. t4, p = 0.04) and night-time (t0 vs. t4, p = 0.003) cough scores.
A significant difference, considering the study product, was also found in the following intra-group analyses: day-time
scores at t4 vs. t8 (p =0.01) and at t0 vs. t8 (p = 0.001); night-time scores at t4 vs. t8 (p = 0.05), and at t0 vs. t8 (p = 0.005).
Considering a subgroup of patients with higher cough (≥3) scores, 92.9% of them in the study product group improved
at t0 vs. t4 day-time.
Conclusions: Grintuss® pediatric syrup showed to possess an interesting profile of efficacy and safety in the treatment
of cough persisting more than 7 days.
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Cough is an extremely common problem in pediatrics
[1], it is related to a poor quality of life and absence
from school for children and from work for parents;
moreover night-time cough is the most difficult to solve
and to be tolerated. Anatomically the upper airway
comprehend nasal cavities, pharynx and larynx. Upper* Correspondence: gl.marseglia@smatteo.pv.it
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unless otherwise stated.respiratory tract infections represent the most common
acute illness in the community. They can range from the
self-limiting common cold, to viral and bacterial infec-
tions of pharynx and larynx and to inflammation from
irritating agents. Lower respiratory infections represent a
less frequent problem in children, even if a more serious
one, and they involve trachea, bronchi and lungs. A
persisting cough is often accompanied by upper respira-
tory tract infection (URTIs) [2,3], whereas other causes
may be exposure to passive tobacco smoke, pollutants,
aerosols and dust. A persistent cough is defined as al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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1 For a short period (approximately a few minutes)
2 For 2 short periods (approximately 10 minutes)
3
Frequent cough that does not interfere with
normal activities
4
Frequent cough that interferes with normal
activities




1 Only at awakening/only before falling asleep
2 Awaken once/early awaken due to cough
3 Frequently awaken due to cough
4 Frequent cough for the most part of the night
5 Disturbing cough
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According to literature two out of three children aged
between 0 and 4 years visit their GP at least once a year
with an acute respiratory infection and up to three-
quarters of these will have a cough [4]. Prospective stu-
dies of acute cough in young children in general practice
have suggested that about 50% recover by 10 days and
90% by 3 weeks, so 10% of children still have problems
in the third to fourth weeks [5].
In recent researches, many of the most common me-
dications used to treat cough are nowadays studied to
evaluate not only their efficacy, but also safety, in order
to underline how benefits/risks ratio tent toward their
beneficial effects [6-8]. In most cases, the pharmaco-
logical treatment aims to suppress the symptom (cough
suppressant therapy), with synthetic agents that play an
inhibitory effect on the cough reflex or act as mucolytic
drugs, with the simple intent to reduce both intensity
and frequency of cough in the short term, increasing the
possibility to experience side effects [9-12].
Respiratory viruses, bacteria and irritants would cause
a widespread inflammation of the mucosa of several ana-
tomical areas, especially the upper respiratory tract mu-
cosa, desquamation of the epithelial cells and damage of
the nerve endings, which may then lead to a certain de-
gree of hyper-reactivity of the cough reflex. Such a local
environment may increase the sensitivity of the mucosa
towards certain stimuli and local irritants, inducing a
vicious circle that leads to an increased mucosal damage
[13], that may facilitate irritating agents access towards
the nerve endings of the sub mucosa by activating con-
striction and bronchial reflexes [14-16].
Starting from the above assumptions, it seems reason-
able that the protective effect exerted by a mechanical
barrier may represent a reliable therapeutic approach,
different from the past, and able to more effectively limit
the damage caused by micro-organisms and irritants on
the mucosa due to an indirect anti-inflammatory action.
The barrier effect could be achieved by a particular
combination of functional components (obtained from
natural molecular complexes) such as resins, polysaccha-
rides, saponins and flavonoids that are able to exert an
indirect anti-inflammatory effect on the upper respira-
tory tract area [17-19].
In the light of these considerations, it might be interes-
ting and innovative to investigate the efficacy of a mecha-
nical and non-pharmacological therapeutic intervention in
the treatment of persisting cough.
Aim of the present randomized, double-blind, placebo-
controlled trial was therefore to assess the effectiveness of
the medical device Grintuss® (the study product, classi-
fied according to the Directive 93/42/EC, containing a
combination of specific fractions of substances such as
resins, polysaccharides, saponins, flavonoids and sugars)in comparison with a placebo, in the treatment of cough
persisting for more than 7 days.
Methods
In the present randomized, parallel groups, double-blind
vs. placebo study, 102 children aged 3 to 6 years (51 for
each group) were consecutively enrolled. They were
referred for persisting cough (at least 7 days up to
3 weeks, not treated with any other antitussive product)
to the Pediatric Allergology and Pulmonology Unit of
the Azienda Ospedaliero-Universitaria of Udine (Italy),
or to the Immuno-Pneumo-Allergy Unit of the Department
of Pediatrics of the University of Pavia (Italy).
Informed parental consent was obtained to be eligible
for enrollment into the study. The study was performed
according to the rules of Pavia and Udine Universities
Ethics Committees and conducted by the CRO SPRIM
ALS GCP Srl Italy.
The primary endpoint of the study was to evaluate
the clinical efficacy of Grintuss® assessing the changes in
the day- and night-time cough score [20] (evaluated by
the specialist during the visits at t4 and t8 and recorded
by parents in a daily diary) after 4 and 8 days of product
administration (Table 1) [21-25]. All adverse events and
severe adverse events were recorded and evaluated.
The study product (a syrup containing specific fractions
of substances such as resins, polysaccharides, saponins,
flavonoids and sugars derived from Grindelia robusta,
Plantago lanceolata, Helichrysum italicum, honey) was
administered as it was, 4 doses a day, 5 ml each, for 8 days.
The placebo was a syrup having the same organoleptic
properties, viscosity and texture of the study product; it
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tassium (E202), acesulfame K, lemon and orange flavours,
plant charcoal and beta-carotene and it was administered
according to the same modalities of the study product.
Both of them were supplied by Aboca S.p.A. Società
Agricola, Italy. During the whole study period the follo-
wing treatments were not allowed: immunostimulants or
immunoregulators of biological origin, corticosteroids, an-
tibiotics, antihistaminics and bronchodilators.
The sample size was obtained assuming a mean cough
score of 3 points in both groups at baseline, and a mean
change in cough score of 2 and 1 points respectively for
placebo and treatment group at the end of the study,
with 1.3 standard deviation.
Data from both centers participating in this study were
combined. Data were summarized for demographic cha-
racteristics, efficacy observations and measurements,
safety observations and evaluations using standard de-
scriptive statistics. Safety was assessed on the frequency
of adverse reactions attributable to the study product,
summarized and described for each treatment group.
Changes between groups in cough score were assessed
with Student’s T-test and pooled T-test. Differences
in efficacy between treatment and placebo groups for
children with intense cough (scores ≥3) were tested by
means of Fisher exact test.
Results
All the patients (102 screened and 102 randomized to
study product (n = 51) or placebo (n = 51)) were analyzed
according to the intention- to-treat (ITT) population, that
includes all randomized patients who took at least one
dose of study product or placebo. Forty-four patients ran-
domized to placebo and 47 patients randomized to studyTable 2 Demographic and anamnestic data from participants
Mean
Study product Age (years) 4.90
n = 51 Height (m) 1.08
28 boys Weight (kg) 19.70
BMI 16.64
Patients with siblings 36
Presence of fever 2
Cough score 2.62
Placebo Age (years) 4.43
n = 51 Height (m) 1.05
26 boys Weight (kg) 18.27
BMI 16.29
Patients with siblings 24
Presence of fever 2
Cough score 2.60treatment completed the study; two patients discontinued
the study (both randomized to placebo). No patients dis-
continued for adverse events, severe adverse events or
other safety reasons.
Demographic data and other baseline characteristics
Subjects demographics and anamnestic data are summa-
rized in Table 2, and include age (years), gender, height
(m), weight (kg), body mass index (kg/m2), numbers, if
any, of siblings, and presence of fever. The study product
group and the placebo group presented comparable
demographic characteristics, without any meaningful dif-
ferences as regards to all the evaluated parameters. As
for the results of the cough scores, there was no signifi-
cant difference in the two groups at t0.
Analysis of safety variables
A total of 34 subjects experienced an adverse event
(17 in the treatment group and 17 in the placebo group)
and the total number of adverse events was 55 (24 in the
treatment group and 31 in the placebo group). Adverse
events included mainly the appearance of fever, cold and
episodes of vomiting. No severe adverse event was re-
corded. All adverse events were assessed as “unrelated”
to the study products and the subjects recovered in all
cases.
Cough score and efficacy of the product
As regard to the primary endpoint of the study (change
of cough score between t0-enrolment in the study,
t4-first control visit and t8-end of the treatment), when
symptoms score was compared between study product
and placebo, significant differences were detected fa-
vouring the study product.at the inclusion visit (t0)
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compared with the placebo group, a significant diffe-
rence (t4 study treatment vs. t4 placebo, p = 0.03, T-test)
was observed at t4 in night-time cough score (Figure 1).
Considering the intra-group analysis, only the study
product group registered a significant improvement
from t0 to t4 in both day-time (t0 vs. t4, p = 0.04, T-test)
and night-time (t0 vs. t4, p = 0.003, T-test) cough scores
(Figures 1 and 2).
For the study product group, there was also a significant
difference in day-time cough scores, comparing t4 vs. t8
(intra-group analysis, p =0.01, T-test) and t0 vs. t8 (intra-
group analysis, p = 0.001, T-test) (data not shown). More-
over, a significant difference has been found in night-time
scores comparing t4 vs. t8 (intra-group analysis, p = 0.05,
T-test) and t0 vs. t8 (intra-group analysis, p = 0.005,T-test)
(data not shown).
In order to assess the treatment effects in children with
more intense cough, evidenced by a cough score ≥ 3, a
subgroup analysis was performed splitting all the par-
ticipant data into two subgroups (≥3 and <3). Consi-
dering day-time cough, 13 (92.9%) out of 14 children in
the study group with a t0 score ≥ 3 improved at t4,
reporting a score < 3 (p = 0.03 Fisher-test) (Figure 3).
Discussion
In children, in order to treat an episode of cough, thera-
pies need to show a satisfactory safety profile and efficacy.
Cough has a high frequency in pediatrics; it tends to per-
sist, to generate intense discomfort in both the child and























Figure 1 Night-time cough score. Night-time cough score measured at d
product and placebo groups. Means (black dots) and corresponding standa
score for the study product group among time (T-test, ** p = 0.003), and a
product and placebo groups at t4 (T-test, * p = 0.03).prescriptions of antibiotics and other treatments that may
be associated to significant side effects [26]. Despite a cer-
tain number of studies, to date, a specific effective and safe
treatment for cough has not yet been developed; such a
treatment should improve both acute cough and cough
persisting more than 7 days.
We then evaluated the efficacy of the study product, a
medical device (Class IIa according to the definition of art.
1 of Directive 93/42/EC), whose effects can be exerted by
acting as a mechanical barrier, in patients with a cough
persisting for more than 7 days. It contains functional
components selected for their ability to exert a barrier
effect on the mucosa, and for their indirect anti-inflamma-
tory activity. The study product is the result of a com-
bination of specific fractions of substances such as resins,
polysaccharides, saponins, flavonoids and sugars derived
from Grindelia robusta, Plantago lanceolata, Helichrysum
italicum, honey. Preclinical data by in vitro experimental
assays strongly support that the study product possesses
adhesive properties on human oral mucosa (under publi-
cation) and exerts a barrier effect against irritant agents
even showing an indirect anti-inflammatory action.
Resins have adhesive properties, while polysaccharides
have shown to have both adhesive and emollient pro-
perties [27-29]. Together, they create the mechanical
barrier that limits the contact between irritants or micro-
organisms and the upper respiratory tract mucosa, there-
fore reducing both the stimulation of nerve endings and
the inflammation. Saponins are known for their ability to
lower the surface tension [30]; thanks to this property,
they reduce the viscosity of the mucus allowing an easierT(0) T(4)
Placebo
*
ifferent times (day 0 and day 4) in patients enrolled for both study
rd deviations show a significant decrease in mean night-time cough





















Figure 2 Day-time cough score. Day-time cough score measured at different times (day 0 and day 4) in patients enrolled for both study product
and placebo groups. Means (black dots) and corresponding standard deviations show a significant decrease in mean day-time cough score for the
study product group among time (T-test, * p = 0.04).
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turize the mucosa making the mucus less viscous and eas-
ier to be expelled [29]. The results of this study allow us
to hypothesize that the study product can be helpful in
acute cough and in cough that tends to persist even more
than seven days (Figure 1). Moreover, reducing the night-
time cough score at t4 (Figure 1), it is possible to achieve






























Figure 3 Day-time cough score improvement in subgroups of patient
subgroups of children with score≥ 3 in both treatment groups, between t
group reporting a score≥ 3 at t0, 13 (92.9%) improved, reporting a score <
reporting a score≥ 3 at t0, 7 (53.8%) improved reporting a score < 3 at t4.
cough score between study product group and placebo group, at differenis less easy to control, and it creates great discomfort and
causes loss of sleep both in children and parents.
The fact that the study product is effective since the
first days of treatment is definitely an interesting feature,
especially considering that parents, after one week of
symptoms, may start to worry about it, and may seek
other therapeutic intervention exposing the child to the





s with cough score ≥ 3 at t0. It is shown the cough score in
0 and t4. As regards day-time cough in 14 children in the treatment
3 at t4. As regards day-time cough in 13 children in the placebo group
Fisher test shows a significant decrease of patients with day-time acute
t times (day 0 and day 4) (* p = 0.03).
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study product, since there has not been any relevant ad-
verse event related to use of the product.
Grintuss® syrup is on the market since more than
10 years, during which the post-marketing surveillance
system, in compliance with Directive 93/42/EC, has not
registered incident or side effects related to the Medical
Device. Grintuss® should not be used in case of known
hypersensitivity to the components of medical device.
No other contraindication have been registered. The
present study confirms the safety of the study product.
Conclusion
The results of this study support the evidence that
Grintuss® pediatric syrup possesses an interesting profile
of efficacy and safety in the treatment of cough persist-
ing for more than 7 days. The treatment with Grintuss®
is safe and effective in the relief of cough, starting on
onset of application. The mechanical barrier, limiting the
contact with external irritant agents or micro-organisms,
helps the physiological recovery of the mucosa. The de-
crease of cough supports the protective role of Grintuss®
thus showing an improvement in health. This effect
moreover is especially evident at night.
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